Very recently, zoledronic acid was proven to enhance the effect of EGFR-inhibitors and even to overcome resistance acquired through the gatekeeper mutation T790M in non-small cell lung cancer, breast cancer and colorectal cancer [46, 47]. The gene discussed is EGFR; the disease is breast carcinoma.